Ionizable Cationic Lipid Composition for Low-Toxicity Nucleic Acid Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cationic lipid compositions for delivering nucleic acids face challenges in safety, efficacy, and specificity, with increased complexity leading to potential toxicity and limited clinical application.

Innovation Solution

A novel cationic lipid compound of Formula (I) and its derivatives, such as YK-201, YK-202, and YK-209, designed with specific structural variations, enhance encapsulation, transfection efficiency, reduce cytotoxicity, and improve mRNA expression and duration in animals compared to prior art compounds.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cationic lipid compositions are used for nucleic acid delivery, then delivery function is achieved, but safety and specificity deteriorate due to increased complexity and potential toxicity

Engineering Contradiction:

Improvedelivery efficacyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure parameters of cationic lipids by introducing specific structural features (G1, G2, G3 linkers with defined carbon chain lengths and functional groups) to optimize the balance between delivery efficacy and toxicity reduction

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite lipid structures combining cationic head groups with specific hydrophobic tails and linker moieties, forming a composite material that achieves both effective nucleic acid delivery and reduced cytotoxicity compared to conventional cationic lipids

Inventive Principle:

Principle #40Composite materials

2Reliability

If complex lipid nanoparticle compositions are used, then delivery capability is improved, but device complexity increases complicating production

Engineering Contradiction:

Improvedelivery capabilityVSAvoidproduction complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The cationic lipid molecule is segmented into distinct functional domains (charged head group, hydrophobic tail, and specific linker regions G1-G3), allowing systematic optimization of each segment's contribution to delivery capability while maintaining relatively simple overall structure for production

Inventive Principle:

Principle #1Segmentation

3Reliability

If conventional cationic lipids are used, then basic transfection is achieved, but transfection efficiency and encapsulation rates remain insufficient

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidencapsulation rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent systematically varies structural parameters including carbon chain lengths in G1 (C1-C6), G2 (C2-C8), alkyl groups (R1: C6-C20, R2: C12-C25), and G3 functional groups to optimize both transfection efficiency and encapsulation capacity of the cationic lipids

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260007601A1Ionizable cationic lipid compound and composition for delivering nucleic acid and use thereof

Publication Date: 2026.01.08 BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

AI summary

A compound of Formula (I) or an N-oxide, a solvate, a pharmaceutically acceptable salt or a stereoisomer thereof is an ionizable cationic lipid compound.